Infectious Diseases

Back to articles

First Agent in Ketolide Class Still Months Away


Telithromycin (Ketek—Aventis) has been tentatively approved by FDA for community-acquired pneumonia, acute bacterial complications of chronic bronchitis, and acute bacterial sinusitis. But FDA’s approval of the latter two indications came with an unusual request for more data, so approval of the agent is not likely until 2002. In addition, FDA rejected an indication for treatment of tonsillitis/pharyngitis.


Preston SL, Drusano GL. Telithromycin: a once-daily, broad-spectrum ketolide for treatment of various respiratory infections. Formulary. 2001;36:101–35.

Bryskier A. Ketolides—telithromycin, an example of a new class of antibacterial agents. Clin Microbiol Infect. 2000;6:661–9.